Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls

被引:42
作者
Francois, Achille [1 ]
Bouzelha, Mohammed [1 ]
Lecomte, Emilie [1 ]
Broucque, Frederic [1 ]
Penaud-Budloo, Magalie [1 ]
Adjali, Oumeya [1 ]
Moullier, Philippe [1 ]
Blouin, Veronique [1 ]
Ayuso, Eduard [1 ]
机构
[1] Univ Nantes, Ctr Hosp Univ, INSERM UMR1089, Nantes, France
关键词
ADENOASSOCIATED VIRUS TYPE-2; CELL-LINES; 2ND-STRAND SYNTHESIS; CAPSID PROTEIN; VIRAL VECTORS; TRAFFICKING; ADENOVIRUS; REP; GENERATION; TITER;
D O I
10.1016/j.omtm.2018.07.004
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although the clinical use of recombinant adeno-associated virus (rAAV) vectors is constantly increasing, the development of suitable quality control methods is still needed for accurate vector characterization. Among the quality criteria, the titration of infectious particles is critical to determine vector efficacy. Different methods have been developed for the measurement of rAAV infectivity in vitro, based on detection of vector genome replication in trans-complementing cells infected with adenovirus, detection of transgene expression in permissive cells, or simply detection of intracellular vector genomes following the infection of indicator cells. In the present study, we have compared these methods for the titration of infectious rAAV8 vector particles, and, to assess their ability to discriminate infectious and non-infectious rAAV serotype 8 particles, we have generated a VP1-defective AAV8-GFP vector. Since VP1 is required to enter the cell nucleus, the lack of VP1 should drastically reduce the infectivity of rAAV particles. The AAV8 reference standard material was used as a positive control. Our results demonstrated that methods based on measurement of rAAV biological activity (i.e., vector genome replication or transgene expression) were able to accurately discriminate infectious versus non-infectious particles, whereas methods simply measuring intracellular vector genomes were not. Several cell fractionation protocols were tested in an attempt to specifically measure vector genomes that had reached the nucleus, but genomes from wild-type and VP1-defective AAV8 particles were equally detected in the nuclear fraction by qPCR. These data highlight the importance of using suitable controls, including a negative control, for the development of biological assays such as infectious unit titration.
引用
收藏
页码:223 / 236
页数:14
相关论文
共 48 条
[1]   Sodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System [J].
Adamson-Small, Laura ;
Potter, Mark ;
Byrne, Barry J. ;
Clement, Nathalie .
HUMAN GENE THERAPY METHODS, 2017, 28 (01) :1-14
[2]   ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES [J].
ATCHISON, RW ;
CASTO, BC ;
HAMMON, WM .
SCIENCE, 1965, 149 (3685) :754-&
[3]   Intracellular route and biological activity of exogenously delivered Rep proteins from the adeno-associated virus type 2 [J].
Awedikian, R ;
François, A ;
Guilbaud, M ;
Moullier, P ;
Salvetti, A .
VIROLOGY, 2005, 335 (02) :252-263
[4]   Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material [J].
Ayuso, Eduard ;
Blouin, Veronique ;
Lock, Martin ;
McGorray, Susan ;
Leon, Xavier ;
Alvira, Mauricio R. ;
Auricchio, Alberto ;
Bucher, Stephanie ;
Chtarto, Abdelwahed ;
Clark, K. Reed ;
Darmon, Christophe ;
Doria, Monica ;
Fountain, Will ;
Gao, Guangping ;
Gao, Kai ;
Giacca, Mauro ;
Kleinschmidt, Juergen ;
Leuchs, Barbara ;
Melas, Catherine ;
Mizukami, Hiroaki ;
Mueller, Marcus ;
Noordman, Yvet ;
Bockstael, Olivier ;
Ozawa, Keiya ;
Pythoud, Catherine ;
Sumaroka, Marina ;
Surosky, Richard ;
Tenenbaum, Liliane ;
van der Linden, Inge ;
Weins, Brigitte ;
Wright, J. Fraser ;
Zhang, Xinhua ;
Zentilin, Lorena ;
Bosch, Fatima ;
Snyder, Richard O. ;
Moullier, Philippe .
HUMAN GENE THERAPY, 2014, 25 (11) :977-987
[5]   Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors [J].
Boutin, Sylvie ;
Monteilhet, Virginie ;
Veron, Philippe ;
Leborgne, Christian ;
Benveniste, Olivier ;
Montus, Marie Francoise ;
Masurier, Carole .
HUMAN GENE THERAPY, 2010, 21 (06) :704-712
[6]   Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system [J].
Burger, C ;
Gorbatyuk, OS ;
Velardo, MJ ;
Peden, CS ;
Williams, P ;
Zolotukhin, S ;
Reier, PJ ;
Mandel, RJ ;
Muzyczka, N .
MOLECULAR THERAPY, 2004, 10 (02) :302-317
[7]   Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses [J].
Calcedo, Roberto ;
Vandenberghe, Luk H. ;
Gao, Guangping ;
Lin, Jianping ;
Wilson, James M. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (03) :381-390
[8]  
Chadeuf G, 2000, J GENE MED, V2, P260
[9]   CELL-LINES FOR THE PRODUCTION OF RECOMBINANT ADENOASSOCIATED VIRUS [J].
CLARK, KR ;
VOULGAROPOULOU, F ;
FRALEY, DM ;
JOHNSON, PR .
HUMAN GENE THERAPY, 1995, 6 (10) :1329-1341
[10]   A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype [J].
Ellis, Brian L. ;
Hirsch, Matthew L. ;
Barker, Jenny C. ;
Connelly, Jon P. ;
Steininger, Robert J., III ;
Porteus, Matthew H. .
VIROLOGY JOURNAL, 2013, 10